Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for MRI-detected subclinical inflammation in ACPA-positive arthralgia
2014-000555-93Phase 3Completed
- Sponsor
- University Hospital Erlangen
- Start
- May 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in arthralgia and rheumatoid arthritis (RA) comparing Abatacept subcutaneous weekly with Placebo (2 arms). Primary endpoint: Improvement in MRI inflammation. Started May 2014; status: completed.
02
Drugs
abatacept
03
Conditions
arthralgiarheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-000555-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000555-93.